{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:19:15Z","timestamp":1776388755753,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jhep.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T19:46:05Z","timestamp":1682279165000},"page":"314-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A randomized-controlled trial of SOF\/VEL\/VOX with or without ribavirin for retreatment of chronic hepatitis C"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-6894","authenticated-orcid":false,"given":"Mohamed","family":"El-Kassas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Emadeldeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Esmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Ali","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5191-2278","authenticated-orcid":false,"given":"Fathiya","family":"El-Raey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3531","authenticated-orcid":false,"given":"Stephen E.","family":"Congly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-272X","authenticated-orcid":false,"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2023.04.011_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","article-title":"Natural history of hepatitis C","volume":"44","author":"Lingala","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jhep.2023.04.011_bib2","unstructured":"World health organization (WHO), Hepatitis C fact sheet, Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c [accessed 30 Sep 2022]."},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2023.04.011_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection\u00a0with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.04.011_bib4","first-page":"117","article-title":"HCV treatment failure in the era of DAAs","author":"Hassany","year":"2017","journal-title":"Adv Treat Hepat C B"},{"issue":"3","key":"10.1016\/j.jhep.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0039-1687823","article-title":"Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures","volume":"39","author":"Pawlotsky","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2023.04.011_bib6","unstructured":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, Available from: https:\/\/www.hcvguidelines.org\/treatment-experienced [accessed on 04 dec 2021]."},{"issue":"5","key":"10.1016\/j.jhep.2023.04.011_bib7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.04.011_bib8","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","year":"2018"},{"issue":"1","key":"10.1016\/j.jhep.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2015.09.009","article-title":"Ideal oral combinations to eradicate HCV: the role of ribavirin","volume":"64","author":"Hezode","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2023.04.011_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2893.1998.00099.x","article-title":"Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients","volume":"5","author":"Zoulim","year":"1998","journal-title":"J\u00a0Viral Hepat"},{"issue":"19","key":"10.1016\/j.jhep.2023.04.011_bib11","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1001\/archinte.165.19.2206","article-title":"Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials","volume":"165","author":"Brok","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jhep.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.jhep.2023.04.011_bib13","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/jvh.13162","article-title":"Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure","volume":"26","author":"Lu","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.jhep.2023.04.011_bib14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhep.2023.04.011_bib15","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1093\/cid\/ciaa1510","article-title":"Salvage therapy with sofosbuvir\/velpatasvir\/voxilaprevir in DAA-experienced patients: results from a prospective Canadian registry","volume":"72","author":"Onofrio","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"S1","key":"10.1016\/j.jhep.2023.04.011_bib16","first-page":"939A","article-title":"Safety and efficacy of velpatasvir, sofosbuvir and voxilaprevir-based regimens for the treatment of HCV genotype 1-6: results of the HCV-TARGET study","volume":"70","author":"Zeuzem","year":"2019","journal-title":"Hepatology"},{"issue":"38","key":"10.1016\/j.jhep.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","author":"Omran","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.jhep.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2023.04.011_bib19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"22","key":"10.1016\/j.jhep.2023.04.011_bib20","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2023.04.011_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/jmv.27165","article-title":"Hepatitis C virus genotype 4: a poorly characterized endemic genotype","volume":"93","author":"Leumi","year":"2021","journal-title":"J\u00a0Med Virol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:50:52Z","timestamp":1759175452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0168827823002349"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.04.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized-controlled trial of SOF\/VEL\/VOX with or without ribavirin for retreatment of chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}